Q3 FY26 results: consolidated net loss of Rs 12.97 Cr versus profit year-ago
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis posted a consolidated net loss of Rs 12.97 Cr in Q3 FY26 versus a profit of Rs 65.27 Cr in Q2 FY26 and Rs 4.63 Cr in Q3 FY25. Standalone loss widened to Rs 23.13 Cr from Rs 13.60 Cr in Q2 FY26. For nine months, consolidated PAT swung to a Rs 75.70 Cr profit from a Rs 39.85 Cr loss last year, on revenue of Rs 2,080.50 Cr versus Rs 1,995.16 Cr. Q3 operating revenue rose to Rs 719.80 Cr from Rs 682.34 Cr year-on-year. Operating margin slipped to 15.71 percent from 22.81 percent sequentially. Auditor T R Chadha gave an unmodified review but drew attention to Note 4 on goodwill amortisation.
Sharp sequential profit drop despite improved nine-month performance. Auditor flagged goodwill amortisation treatment as an emphasis matter.